Subsequently, when testing the GL-261 model system, a murine GBM line widely used for assessing immune checkpoint inhibitor therapies in vivo, we noted a decrease in PD-L1 levels upon treatment with Alisertib (Figure 2C). The gene discussed is CD274; the disease is glioblastoma.